Drug profile · INN
ergotamine tartrate
ERGOMAR
ergotamine tartrate (ERGOMAR) is a adrenergic receptor alpha agonist. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — ergotamine tartrate
- US status
- approved
- Class
- —
- Route
- INHALATION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ergotamine tartrate (ERGOMAR) is a adrenergic receptor alpha agonist. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor alpha agonist
Primary target: Adrenergic receptor alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ergotamine tartrate?
ergotamine tartrate (ERGOMAR) is a adrenergic receptor alpha agonist. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for ergotamine tartrate?
ERGOMAR is a marketed brand name for ergotamine tartrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ergotamine tartrate?
ergotamine tartrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.